Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 10:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Long Term Follow-up Clear all
Enrolling by invitation No phase listed Observational

Long-Term Follow-up Study of Participants Exposed to Renal Autologous Cell Therapy Frozen Product

NCT06790498
View directory record Official record
Conditions
Diabetic Kidney Disease, Chronic Kidney Disease
Interventions
Renal Autologous Cell Therapy (REACT)
Biological
Lead sponsor
Prokidney
Industry
Eligibility
30 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
Meridian, Idaho
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Sep 25, 2026, 10:57 PM EDT
Recruiting No phase listed Observational

A Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients With nAMD

NCT06346600
View directory record Official record
Conditions
Neovascular (Wet) Age-related Macular Degeneration
Interventions
SKG0106
Genetic
Lead sponsor
Skyline Therapeutics
Industry
Eligibility
50 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
3
States / cities
Boston, Massachusetts • Katy, Texas • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 25, 2026, 10:57 PM EDT
Enrolling by invitation No phase listed Observational

Long Term Follow-up Study of AAVAnc80-hOTOF Gene Therapy

NCT06696456
View directory record Official record
Conditions
Otoferlin Gene-mediated Hearing Loss
Interventions
Not listed
Lead sponsor
Akouos, Inc.
Industry
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2033
U.S. locations
3
States / cities
Iowa City, Iowa • Boston, Massachusetts • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Sep 25, 2026, 10:57 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Long-Term Follow-Up of Recipient of Gene Transfer Research

NCT01492036
View directory record Official record
Conditions
Retroviridae Infections, Cancer
Interventions
Blood Tests, Questionnaires
Other · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Sep 25, 2026, 10:57 PM EDT
Completed No phase listed Observational

Long-term Follow-up of HIV Infected Patients Identified During Early Infection

NCT00086372
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
22
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2012 · Synced Sep 25, 2026, 10:57 PM EDT
Active, not recruiting Phase 1 Interventional

A Long-term Follow up Study of EXG102-031 in Patients With wAMD (Everest LTFU)

NCT06817343
View directory record Official record
Conditions
Neovascular Age-Related Macular Degeneration (nAMD), Neovascular (Wet) Age-related Macular Degeneration (AMD)
Interventions
Aflibercept (2.0 mg)
Biological
Lead sponsor
Exegenesis Bio
Industry
Eligibility
Not listed
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
2
States / cities
Reno, Nevada • Erie, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Sep 25, 2026, 10:57 PM EDT
Completed Phase 3 Interventional Results available

Follow up Study to Assess Long Term Safety and Outcomes in Infants and Children Born to Mothers Participating in Retosiban Treatment Studies

NCT02292784
View directory record Official record
Conditions
Obstetric Labour, Premature
Interventions
Retosiban, Atosiban, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
10 Weeks to 20 Weeks
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Park Ridge, Illinois • Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 8, 2020 · Synced Sep 25, 2026, 10:57 PM EDT
Recruiting No phase listed Observational

Long-term Follow-up of a Cochlear Implant With Dexamethasone Eluting Electrode Array

NCT06936449
View directory record Official record
Conditions
Sensorineural Hearing Loss, Bilateral Hearing Loss
Interventions
CI632D, CI632
Device
Lead sponsor
Cochlear
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
3
States / cities
Englewood, Colorado • Iowa City, Iowa • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 25, 2026, 10:57 PM EDT
Enrolling by invitation Phase 2 Interventional

Long-term Follow-up of Gene Therapy for Radiation-Induced Xerostomia

NCT06544798
View directory record Official record
Conditions
Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of the Upper Aerodigestive Tract, Excluding the Parotid Glands
Interventions
AAV2-hAQP1
Genetic
Lead sponsor
MeiraGTx, LLC
Industry
Eligibility
18 Years and older
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
7
States / cities
Gilbert, Arizona • Miami, Florida • Iowa City, Iowa + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Sep 25, 2026, 10:57 PM EDT
Active, not recruiting No phase listed Observational

Long-Term Follow-up Study for Patients From AVXS-101-CL-101

NCT03421977
View directory record Official record
Conditions
Spinal Muscular Atrophy 1
Interventions
Onasemnogene Abeparvovec-xioi
Biological
Lead sponsor
Novartis Gene Therapies
Industry
Eligibility
Not listed
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2030
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Sep 25, 2026, 10:57 PM EDT
Recruiting No phase listed Observational

Long-term Follow-up Study of Patients Receiving CAR-T Cells

NCT03375619
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Lymphomas Non-Hodgkin's B-Cell, Lymphoma, Small Lymphocytic, Mantle Cell Lymphoma, Central Nervous System Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Burkitt Lymphoma, Multiple Myeloma
Interventions
Long-Term Follow-Up of Participants who Received CAR-T cells
Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 80 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2035
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 9, 2025 · Synced Sep 25, 2026, 10:57 PM EDT
Active, not recruiting No phase listed Observational

Follow up of Intravesical N-803 Plus BCG in BCG-Naive Non-Muscle Invasive Bladder Cancer (NMIBC)

NCT05981131
View directory record Official record
Conditions
Non Muscle Invasive Bladder Cancer
Interventions
N803 plus Bacillus Calmette-Guerin (BCG)
Drug
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
Not listed
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Sep 25, 2026, 10:57 PM EDT
Completed Phase 4 Interventional Results available

Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409

NCT02255656
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
alemtuzumab GZ402673
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
1,062 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
52
States / cities
Cullman, Alabama • Phoenix, Arizona • Tucson, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2022 · Synced Sep 25, 2026, 10:57 PM EDT
Withdrawn No phase listed Observational

Long-Term Follow-Up Safety Study of Subjects Treated with SynKIR-110 in Cancer Studies

NCT06377202
View directory record Official record
Conditions
Cancer
Interventions
Not listed
Lead sponsor
Verismo Therapeutics
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2038
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 6, 2024 · Synced Sep 25, 2026, 10:57 PM EDT
Completed Phase 3 Interventional

Long-term Follow-up Study Designed to Evaluate the Relative Risk of Two Colonoscopy Schedules for Patients With Small Polyps

NCT00032344
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Colonoscopy
Procedure
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
50 Years to 75 Years
Enrollment
3,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2007
U.S. locations
13
States / cities
Phoenix, Arizona • Tucson, Arizona • Long Beach, California + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2018 · Synced Sep 25, 2026, 10:57 PM EDT
Completed No phase listed Observational

TODAY2 Phase 2 Follow-up

NCT02310724
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
TODAY cohort
Other
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
15 Years and older
Enrollment
517 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
15
States / cities
Los Angeles, California • Aurora, Colorado • New Haven, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2021 · Synced Sep 25, 2026, 10:57 PM EDT
Enrolling by invitation Phase 1 Interventional

Long-Term Follow-Up Study of HIV-1 Infected Adults Who Received EBT-101

NCT05143307
View directory record Official record
Conditions
HIV-1-infection
Interventions
EBT-101
Biological
Lead sponsor
Excision BioTherapeutics
Industry
Eligibility
18 Years and older · Male only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2037
U.S. locations
3
States / cities
San Francisco, California • St Louis, Missouri • Camden, New Jersey
Source: ClinicalTrials.gov public record
Updated May 13, 2024 · Synced Sep 25, 2026, 10:57 PM EDT
Recruiting No phase listed Observational

Ethicon Pelvic Mesh Post Market Clinical Follow-up Registry

NCT04829175
View directory record Official record
Conditions
Stress Urinary Incontinence, Pelvic Organ Prolapse
Interventions
Intervention
Device
Lead sponsor
Ethicon, Inc.
Industry
Eligibility
21 Years and older · Female only
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2038
U.S. locations
4
States / cities
New Haven, Connecticut • Durham, North Carolina • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 25, 2026, 10:57 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Long-Term Safety and Antibody Persistence of TDV and the Impact of a Booster Dose

NCT03999996
View directory record Official record
Conditions
Dengue Fever
Interventions
Takeda's Dengue Tetravalent Vaccine (Live, Attenuated) (TDV), Placebo
Biological
Lead sponsor
Takeda
Industry
Eligibility
13 Years to 63 Years
Enrollment
365 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
8
States / cities
Huntsville, Alabama • Peoria, Illinois • Newton, Kansas + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 25, 2026, 10:57 PM EDT
Terminated Not applicable Interventional Results available

Protege Extension Trial - Long Term Follow Up Trial for Subjects Who Completed the Protege Study (CP-MGA031-01)

NCT00870818
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Blood samples for safety, Patient reported outcome questionnaires, Analysis of T-cell subsets
Diagnostic Test · Behavioral
Lead sponsor
MacroGenics
Industry
Eligibility
10 Years to 37 Years
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 8, 2023 · Synced Sep 25, 2026, 10:57 PM EDT
Completed No phase listed Observational Results available

CLBP Single-Arm Long-Term Follow-up Study

NCT05207813
View directory record Official record
Conditions
Chronic Low Back Pain
Interventions
Intracept Procedure
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
25 Years to 70 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Carmel, Indiana • Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 7, 2025 · Synced Sep 25, 2026, 10:57 PM EDT
Active, not recruiting No phase listed Observational

Long-Term Follow-up Study of ADVM-022 in DME (INFINITY-EXT)

NCT05607810
View directory record Official record
Conditions
Diabetic Macular Edema, Diabetic Retinopathy
Interventions
ADVM-022
Genetic
Lead sponsor
Adverum Biotechnologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
6
States / cities
Beverly Hills, California • Reno, Nevada • Philadelphia, Pennsylvania + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2025 · Synced Sep 25, 2026, 10:57 PM EDT
Completed No phase listed Observational

Long Term Follow Up Of Patients Who Have Received Gene Therapy Or Gene Marked Products

NCT00695279
View directory record Official record
Conditions
Severe Combined Immunodeficiency, Malignancy, Hematologic, Neuroblastoma, Neoplasm, Mucopolysaccharidosis I
Interventions
Venipuncture
Procedure
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Not listed
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2024
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 29, 2024 · Synced Sep 25, 2026, 10:57 PM EDT
Recruiting No phase listed Observational

Long-Term Follow-up Study for Subjects With CHB Previously Treated With Imdusiran (AB729)

NCT06277037
View directory record Official record
Conditions
Long Term Follow-up
Interventions
Non-interventional
Other
Lead sponsor
Arbutus Biopharma Corporation
Industry
Eligibility
20 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
3
States / cities
San Diego, California • Miami, Florida • Hillsborough, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced Sep 25, 2026, 10:57 PM EDT